Track Aclarion Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Aclarion Inc. Common Stock ACON · Stock Open Aclarion Inc. Common Stock in new tab

2.44 USD
EPS
-6.96
P/B
0.38
ROE
-58.97
Beta
1.24
Loading chart...
Key Metrics
Earnings dateNov. 11, 2026
EPS-6.96
Book Value6.91
Price to Book0.38
Debt/Equity47.32
% Insiders23.976%
Growth
Revenue Growth0.31%
Estimates
Forward P/E-0.47
Forward EPS-5.47

DCF Valuation

Tweak assumptions to recompute fair value for Aclarion Inc. Common Stock (ACON)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result

Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Aclarion Inc. Common Stock Logo Aclarion Inc. Common Stock Analysis (ACON)

United States Information Technology Official Website Stock

Is Aclarion Inc. Common Stock a good investment? Aclarion Inc. Common Stock (ACON) is currently trading at 2.44 USD.

Earnings Schedule: Aclarion Inc. Common Stock is expected to release its next earnings report on Nov. 11, 2026. The market consensus estimate for Forward EPS is -5.47.

Investor FAQ

Does Aclarion Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Aclarion Inc. Common Stock?

Aclarion Inc. Common Stock is classified as a Stock. You can compare it against its peer in the "Related Symbols" list.

When is the next earnings date?

The next earnings date is projected to be Nov. 11, 2026. The company currently has a trailing EPS of -6.96.

Company Profile

Aclarion, Inc. operates as a healthcare technology company in the United States. It uses magnetic resonance spectroscopy (MRS) combined with proprietary signal-processing biomarkers to optimize clinical treatments. The company develops NOCISCAN, which uses MRS capabilities to non-invasively analyze the chemical makeup of intervertebral discs in the spine. It also provides NOCISCAN MRS Exam Protocol, a custom software protocol for using commercially available MRS pulse sequences in scanning intervertebral discs which extends the time of a standard lumbar MRI exam; and imaging data transfer products, including AMBRA Healthcare, a data transfer platform. In addition, the company offers The NOCISCAN Post-Processor Suite comprising NOCICALC, a Class I medical device that receives the raw un-processed NOCISCAN MRS exam data and post-processes that raw data into final spectra, and performs various degenerative pain biomarker calculations from those spectra, for each disc examined; and NOCIGRAM, which further processes the NOCICALC results into individual NOCISCORES, on a 0-10 scale, that represent the different relative levels of degenerative pain biomarkers the various discs examined in the patient. The company was formerly known as Nocimed, Inc. and changed its name to Aclarion, Inc. in December 2021. Aclarion, Inc. was incorporated in 2008 and is based in Broomfield, Colorado.

Exchange Ticker
NMS (United States) ACON
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Jan. 4, 2024 1:16
Jan. 29, 2025 Needs review
March 28, 2025 1:27
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion